UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended September 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 000-53601

MITESCO, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada		87-0496850
(State Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

505 Beachland Blvd., Suite 1377
Vero Beach, Florida 32963

(Address of principal executive offices) (Zip code)

844-383-8689

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large, accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes ☐ No ☒

As of November 13, 2025, the registrant had 15,093,055 shares of common stock issued and outstanding.

Table of Contents

		Page
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)
	Consolidated Balance Sheets as of September 30, 2025, and December 31, 2024	1
	Consolidated Statements of Operations for the three and nine months ended September 30, 2025, and 2024	2
	Consolidated Stockholder’s Deficit for the three and nine months ended September 30, 2025, and 2024	3
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2025, and 2024	4
	Notes to Consolidated Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	24

Item 4.	Controls and Procedures.	24

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings.	25

Item 1A.	Risk Factors.	26

Item 2.	Sale of Unregistered Securities.	26

Item 3.	Defaults Upon Senior Secured Securities.	26

Item 4.	Mine Safety Disclosures.	26

Item 5.	Other Information.	26

Item 6.	Exhibits.	27

Signatures		28

Table of Contents

MITESCO, INC.

CONSOLIDATED BALANCE SHEETS

	September 30			December 31,
	2025			2024
	(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	321		$	3,402
Accounts receivable		36,300			29,700
Prepaid expenses and other current assets		3,651			4,968
Total current assets		40,272			38,070

Intangible assets, net		125,420			151,771

Total Assets	$	165,692		$	189,841

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities
Accounts payable and accrued liabilities	$	4,301,610		$	4,167,061
Accrued interest		384,605			374,376
Accrued interest - related parties		-			22,547
Derivative liabilities		1,172,020			4,685,675
Royalty payable		150,000			150,000
Deferred revenue		10,000			-
Lease liability - operating leases, current		99,477			99,477
Notes payable		641,666			548,137
Notes payable - related parties		-			64,044
SBA loan payable		374,643			393,761
Other current liabilities		96,136			96,136
Preferred stock dividends payable - related parties		-			14,439
Legal settlements		3,322,834			2,666,675
Series A preferred stock liability, current		7,030,279			5,160,815
Total current liabilities		17,583,270			18,443,143

Series A preferred stock liability, non-current		6,367,442			8,162,644

Total liabilities		23,950,712			26,605,787

Commitments and contingencies (Note 15)

Stockholders’ equity (deficit)

Preferred stock, $0.01 par value, 100,000,000 shares authorized; 10,000,000 shares designated Series D; 10,000 shares designated as Series E; 140,000 shares designated as Series F; and 31,427 shares designated Series X:
Preferred stock, Series D, $0.01 par value, no shares and 25,000 shares issued and outstanding as of September 30, 2025, and December 31, 2024 respectively		-			250
Preferred stock, Series F, $0.01 par value, no shares issued and outstanding as of September 30, 2025, and December 31, 2024 respectively		-			-
Preferred stock, Series X, $0.01 par value, 42,103 and 19,703 shares issued and outstanding at September 30, 2025, and December 31, 2024 respectively		421			197
Common stock, $0.01 par value, 500,000,000 shares authorized, 15,093,055 and 9,762,258 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively		150,931			97,623
Additional paid-in capital		39,758,998			37,341,335
Accumulated deficit		(63,695,370	)		(63,855,351	)
Total stockholders’ equity (deficit)		(23,785,020	)		(26,415,946	)

Total liabilities and stockholders’ equity (deficit)	$	165,692		$	189,841

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

MITESCO, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended						Nine Months Ended
	September 30, 2025			September 30, 2024			September 30, 2025			September 30, 2024
Revenue	$	3,000		$	23,500		$	38,700		$	29,500

OPERATING EXPENSES:
Cost of operations		19,902			8,802			29,953			8,802
General and administrative		993,420			230,940			1,616,687			712,293
Software development		1,100			-			22,222			-

Total operating expenses		1,014,422			239,742			1,668,862			721,095

Net loss from operations		(1,011,422	)		(216,242	)		(1,630,162	)		(691,595	)

OTHER INCOME (EXPENSES):
Interest expense		(386,699	)		(50,979	)		(1,137,355	)		(159,206	)
Interest expense - related parties		-			(10,587	)		(2,297	)		(26,133	)
Gain on termination of operating lease		-			636,485						869,690
Gain on settlement of notes payable		-			693,768						693,768
Gain on settlement of accounts payable		-			1,024,583			562,793			1,024,583
Loss on legal settlement		(500,000	)		-			(500,000	)
Loss on revaluation of Series A Preferred		(387,638	)		-			(646,653	)		-
Gain on revaluation of derivative liabilities		(917,212	)		-			3,513,655			-
Total other income (expense)		(2,191,549	)		2,293,270			1,790,143			2,402,702

Net income (loss)		(3,202,971	)		2,077,028			159,981			1,711,107

Preferred stock dividends		(17,981	)		(18,637	)		(42,609	)		(878,092	)
Preferred stock dividends - related parties		-			(4,888	)		(388	)		(140,888	)

Net income (loss) available to common shareholders	$	(3,220,952	)	$	2,053,503			116,984			692,127

Basic Net income (loss) per common share	$	(0.27	)	$	0.32		$	0.01		$	0.12
Dilutive Net income (loss) per common share	$	(0.27	)	$	0.29		$	(0.20	)	$	0.11

Weighted average shares outstanding – Basic		12,097,157			6,348,878			11,066,795			5,916,675
Weighted average shares outstanding – Diluted		12,097,157			6,984,629			16,399,627			6,552,426

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

MITESCO, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 and 2024

(UNAUDITED)

	Preferred Stock Series D						Preferred Stock Series F						Preferred Stock Series X						Common Stock				Additional Paid-in			Accumulated
	Shares			Amount			Shares			Amount			Shares			Amount			Shares		Amount		Capital			Deficit			Total
Balance, December 31, 2024		25,000		$	250			-		$	-			19,703		$	197			9,762,258	$	97,623	$	37,341,335		$	(63,855,351	)	$	(26,415,946	)

Shares issued for Series A redemptions		-			-			-			-			-			-			1,366,394		13,664		794,539			-			808,203
Shares issued for Series X dividends		-			-			-			-			-			-			28,358		284		12,030			-			12,314
Stock-based compensation		-			-			-			-			-			-			-		-		6,250			-			6,250
Preferred stock dividends		-			-			-			-			-			-			-		-		(12,702	)		-			(12,702	)
Net income		-			-			-			-			-			-			-		-		-			3,450,336			3,450,336

Balance, March 31, 2025		25,000			250			-			-			19,703			197			11,157,010		111,571		38,141,452			(60,405,015	)		(22,151,545	)

Shares issued for Series A redemptions		-			-			-			-			-			-			402,450		4,025		116,269			-			120,294
Shares issued for Series X dividends		-			-			-			-			-			-			33,347		333		11,981			-			12,314
Shares issued for settlement of Series D, notes payable, and accrued liabilities		(25,000	)		(250	)		-			-			-			-			150,000		1,500		41,035			-			42,285
Stock-based compensation		-			-			-			-			-			-			-		-		6,250			-			6,250
Preferred stock dividends		-			-			-			-			-			-			-		-		(12,314	)		-			(12,314	)
Net loss		-			-			-			-			-			-			-		-		-			(87,384	)		(87,384	)

Balance, June 30, 2025		-			-			-			-			19,703			197			11,742,807		117,429		38,304,673			(60,492,399	)		(22,070,100	)

Shares issued for Series A redemptions		-			-			-			-			-			-			2,025,910		20,259		655,643			-			675,902
Shares issued for Series X dividends		-			-			-			-			-			-			99,336		993		16,988			-			17,981
Stock-based compensation		-			-			-			-			22,400			224			1,225,000		12,250		799,675			-			812,149
Preferred stock dividends		-			-			-			-			-			-			-		-		(17,981	)		-			(17,981	)
Net loss		-			-			-			-			-			-			-		-		-			(3,202,971	)		(3,202,971	)
Balance September 30, 2025		-		$	-			-		$	-			42,103		$	421			15,093,055	$	150,931	$	39,758,998		$	(63,695,370	)	$	(23,785,020	)

Balance, December 31, 2023		250,000		$	2,500			20,057		$	201			24,227		$	242			5,567,957	$	55,680	$	47,856,444		$	(62,046,824	)	$	(14,131,757	)

Shares issued for Series X dividends		-			-			-			-			-			-			66,070		661		52,195			-			52,856
Preferred stock dividends		-			-			-			-			-			-			-		-		(638,565	)		-			(638,565	)
Net income		-			-			-			-			-			-			-		-		-			46,524			46,524

Balance, March 31, 2024		250,000			2,500			20,057			201			24,227			242			5,634,027		56,341		47,270,074			(62,000,300	)		(14,670,942	)

Shares issued for compensation		-			-			-			-			-			-			300,000		3,000		99,000			-			102,000
Series X shares issued for compensation														7,200			72			-		-		179,928			-			180,000
Shares issued for Series X dividends		-			-			-			-			-			-			24,555		246		19,396			-			19,642
Preferred stock dividends		-			-			-			-			-			-			-		-		(356,890	)		-			(356,890	)
Net loss		-			-			-			-			-			-			-		-		-			(412,445	)		(412,445	)

Balance, June 30, 2024		250,000		$	2,500			20,057		$	201			31,427		$	314			5,958,582	$	59,587	$	47,211,508		$	(62,412,745	)	$	(15,138,635	)

Shares issued for conversion of account payable		-			-			-			-			-			-			231,886		2,319		58,535			-			60,854
Shares issued for conversion of notes payable and accrued interest		-			-			-			-			-			-			145,493		1,456		175,600			-			177,056
Shares issued for conversion of notes payable and accrued interest – related Parties		-			-			-			-			-			-			45,092		451		37,827						38,278
Shares issued for conversion of Series F preferred shares and accrued dividends		-			-			(5,392	)		(55	)		-			-			1,515,065		15,151		650,489			--			665,585
Shares issued for conversion of Series D preferred shares and accrued dividends		(100,000	)		(1,000	)		-			-			-			-			30,802		308		18,867			-			18,175
Shares issued for conversion of Series X preferred shares		-			-			-			-			(6,840	)		(68	)		56,263		563		(495	)		-			-
Shares issued for Series X dividends		-			-			-			-			-			-			25,573		256		19,396						19,642
Shares issued as compensation		-			-			-			-			-			-			500,000		5,000		101,250						106,250
Preferred stock dividends		-			-			-			-			-			-			-		---		(23,525	)					(23,525	)
Net income																											2,077,028			2,077,028

Balance, September 30, 2024		150,000		$	1,500			14,665		$	146			24,587		$	246			8,508,756	$	85,091	$	48,249,452		$	(60,335,717	)	$	(11,999,292	)

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

MITESCO, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine Months Ended
	September 30, 2025			September 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	159,981		$	1,711,107
Adjustments to reconcile net income to net cash used in operating activities:
Amortization of intangible assets		26,351			-
Original issue discount charged to interest expense		10,000			-
Stock-based compensation		824,649			388,250
Accretion of Series A preferred recorded as interest expense		907,007			-
Loss on revaluation of Series A preferred		646,653			-
Gain on lease terminations		-			(869,690	)
Gain on revaluation of derivative liabilities		(3,513,655	)		(693,768	)
Gain on settlement of note payable		-			(1,024,583	)
Gain on settlement of accounts payable		(562,793	)		-
Changes in operating assets and liabilities:
Accounts receivable		(6,600	)		(29,500	)
Prepaid expenses		1,317			-
Accounts payable and accrued liabilities		1,200,445			(304,504	)
Deferred revenue		10,000			-
Accrued interest		10,229			391,273
Accrued interest - related parties		(22,547	)		31,640
Net cash used in operating activities		(308,963	)		(399,775	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on SBA loan		(19,118	)		(20,241	)
Proceeds from sale of Series A preferred stock		125,000			-
Proceeds from notes payable		200,000			449,000
Net cash provided by financing activities		305,882			428,759

Net change in cash		(3,081	)		28,984
Cash at beginning of period		3,402			2,838
Cash at end of period	$	321		$	31,822

Supplemental disclosure of cash flow information:
Cash paid for interest	$	2,901		$	-
Cash paid for taxes	$			$	-

Supplemental disclosure of financing cash flow information:
Preferred stock dividends	$	42,997		$	1,018,980
Shares issued for Series X dividends	$	42,609		$	92,140
Shares issued for redemption of Series A shares	$	1,604,399		$	-
Shares issued for settlement of Series D, notes payable, and accrued liabilities	$	42,535		$	-
Conversion of accounts payable to common stock	$	-		$	45,000
Conversion of notes payable to common stock	$	-		$	177,056
Conversion of notes payable to common stock - related party	$	-		$	650,940
Conversion of Series F Preferred Stock and accrued dividends to common stock	$	-		$	665,640
Conversion of Series D Preferred Stock and accrued dividends to common stock	$	-		$	19,175
Conversion of Series X Preferred Stock and accrued dividends to common stock	$	-		$	193

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

MITESCO, INC.

UNAUDITED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025

Note 1: Description of Business

Company Overview

Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we shut down our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. In October 2023, the Company changed its domicile from Delaware to Nevada in order to effect reduced costs.

We are a holding company seeking to provide products, services and technology.

In June 2024 we announced the formation of two (2) new wholly owned business units, Centcore, LLC (“Centcore”) that is providing data center services including cloud computing and application hosting, and Vero Technology Ventures, LLC (“VTV”), whose aim is to seek investment and acquisition opportunities, generally in the areas of cloud computing and data center related applications.

Centcore has two (2) areas of focus. The first, generic data center services, is aimed at hosting applications for a specific user, sometimes referred to as “managed services offerings” or MSO, where the client moves the software licensed from various vendors, or internally developed, into our data center where we maintain the computing, communications and backup environment. We currently offer services through a “co-location” agreement with a data center based in Melbourne, Florida, which has relationships with eight (8) other data centers worldwide. Using this approach, we have an ability to rapidly expand the size of our computing resources quickly, at minimal expense. Over time we expect to create similar situations with other data centers worldwide based on our clients’ specific needs. We are also evaluating the development of a network of smaller format (5,000 to 10,000 square foot) data centers inside of existing facilities. We believe that this approach may allow us to expand capacity with a minimal capital expenditure. The existing facilities we are targeting generally have sufficient power, often with a substation nearby. These types of buildings usually have backup generators, HVAC, water and security in a form that would support a data center environment.

We have retained experienced professionals in the data center, cyber security and infrastructure services areas to support our needs on a per hour basis, which we believe will allow us to control our costs relative to business activity, without significant staffing internally.

The Vero Technology Ventures (“VTV”) subsidiary is actively reviewing potential early-stage cloud computing solution vendors and is developing its own artificial intelligence (A.I.) based application set. VTV is currently involved with the formation of a new software development project aimed at applying artificial intelligence (A.I.) to the sales process for various businesses including residential real estate using cloud computing-based software. This initial effort dubbed “Robo Agent”, is expected to be available for initial users in Q4 of FY2025. Later versions may include similar functionality focused on other markets, generally in a “business to consumer” (B2C) selling situation.

In August 2025 we retained a highly qualified executive to begin development of our Robo Agent product set on a consulting basis at a rate of $10,000 per month. We have also recruited three (3) additional contract programmers to accelerate the overall process. In September 2025 we received a contract for development of a new application intended to effect the listing and sale of properties and products specifically related to sports, and the pickleball arena initially. We expect this project to be executed using both internal and external resources and to be completed in late FY2025.

There are several other projects in evaluation, generally aimed at software that would operate on a cloud computing platform such as that which the Company has in its Centcore Data Center.

Table of Contents

Note 2: Going Concern

As of September 30, 2025, the Company had cash and cash equivalents of approximately $300, current liabilities of approximately $17.6 million, and has incurred significant losses from the previous clinic operations. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan. As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the consolidated financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists.

The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

Note 3: Summary of Significant Accounting Policies

Basis of Presentation – The consolidated financial statements are prepared in conformity with accounting principles accepted in the United States of America (“GAAP”).

The consolidated financial statements and related disclosures as of September 30, 2025, are unaudited, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been omitted pursuant to such rules and regulations. In our opinion, these unaudited consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary for the fair statement of the results for the interim periods. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the years ended December 31, 2024, and 2023 included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025. The results of operations for the three and nine months ended September 30, 2025, are not necessarily indicative of the results to be expected for the full year ended December 31, 2025.

Principles of Consolidation – The accompanying consolidated financial statements include the accounts of Mitesco, Inc., and its wholly owned subsidiaries Mitesco NA, LLC, The Good Clinic, LLC, Vero Technology Ventures, LLC, and Centcore, LLC. In addition, we relied on the operating activities of certain legal entities in which we did not maintain a controlling ownership interest, but over which we had indirect influence and of which we were considered the primary beneficiary. These entities are typically subject to nominee ownership and transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. The Company’s management, restrictions and other agreements concerning such nominee-owned entities typically includes both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for these entities to the Company. As such, the Company applies the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 – Consolidation (“ASC 810”), to determine when an entity that is insufficiently capitalized or not controlled through its voting interests, referred to as a variable interest entity should be consolidated. All intercompany balances and transactions have been eliminated.

Revenue Recognition – The Company recognizes revenue in accordance with ASC 606 when it has satisfied the performance obligations under an arrangement with the customer reflecting the terms and conditions under which products or services will be provided, the fee is fixed or determinable, and collection of any related receivable is probable. ASC Topic 606, “Revenue from Contracts with Customers” establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: 1) identify the contract with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to performance obligations in the contract; and 5) recognize revenue as the performance obligation is satisfied.

Table of Contents

Our revenues generally relate to data center services. Revenues are recorded during the period our obligations to provide services are satisfied. The Company’s performance obligation for its revenue stream is to provide the access to its data centers to the customer, and revenues associated with completed sales are recognized at a point in time when they are provided to the customer. There is no significant financing component to the Company’s sales. In circumstances when a customer purchases multiple periods upfront, the Company defers the revenue until the performance obligation has been satisfied. As of September 30, 2025 and December 31, 2024, the Company had $10,000 and $0, respectively, in deferred revenue related to unsatisfied performance obligations that are expected to be recognized during the 12 months following September 30, 2025.

Segments - The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, and income from operations. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.

Per Share Data - Basic income (loss) per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted income (loss) per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options, and convertible instruments.

The following table presents the effect of potential dilutive issuances for the three and nine months ended September 30, 2025 and 2024:

	Three Months Ended					Nine Months Ended
	September 30, 2025			September 30, 2024		September 30, 2025			September 30, 2024
Net income (loss) attributable to common stockholders	$	(3,220,952	)	$	2,053,503	$	116,984		$	692,127
Preferred stock dividends		-			3,883		42,997			27,362
Derivative gain		-			-		58,116			-
Interest expense associated with convertible debt		-			-		(3,513,655	)		-
Net loss for dilutive calculation		(3,220,952	)		2,057,386		(3,295,558	)		719,489

Weighted average shares outstanding		12,097,157			6,348,878		11,066,795			5,916,675
Dilutive effect of preferred stock		-			7,394		-			7,394
Dilutive effect of convertible debt		-			-		5,295,276			-
Dilutive effect of common stock warrants		-			628,357		37,556			628,357
Weighted average shares outstanding for diluted net income (loss) per share		12,097,157			6,984,629		16,399,627			6,552,426

During the three and nine months ended September 30, 2025, the effect of 3,349,430 shares issuable upon the conversion of Series A preferred shares were anti-dilutive and are not included in the computation of dilutive earnings per share.

Financial Instruments and Fair Values - The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. Fair value estimates are made at a specific point in time, based upon relevant market information about the financial instrument. In determining fair value, we use various valuation methodologies and prioritize the use of observable inputs. We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market:

Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable.

Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates.

Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability.

Table of Contents

The use of observable and unobservable inputs and their significance in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the derivative liabilities approximates their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the derivative liabilities as Level 3.

Recent Accounting Standards - In December 2023, the FASB issued Accounting Standard Updated (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company adopted this standard effective January 1, 2025, which did not have a material impact on the Company’s condensed consolidated financial statements.

There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Note 4: Business Acquisition

On December 6, 2024, the Company entered into an Exclusive Source Code License agreement (the “License Agreement”) between AgingTopic, LLC (“AgingTopic”) and the Company where the Company has acquired, subject to certain payment milestones, the source code and business activities of AgingTopic, which constitutes substantially all of AgingTopic’s assets utilized in the creation of advertising revenue from blog postings. The entity that owns the business and source code is controlled by Ms. Amy Lance, the wife of Mack Leath. The agreement calls for a $5,000 cash payment upon execution, and certain royalty payments up to a maximum of $150,000, at which time it becomes a fully paid-up license. The royalty payments are to be repaid at 30% of net collection up to the first $50,000 has been repaid, after which the remaining $100,000 will be repaid based on 15% of net collections. After the payment of the $150,000 license fee, the Company will then pay a commission of 2.5% of net collections until 36 months after the date of the agreement.

This acquisition closed on December 6, 2024. The acquisition of AgingTopic is being accounted for as a business combination under ASC 805. The Company is continuing to gather evidence to evaluate what identifiable intangible assets were acquired, such as a customer list, and the fair value of each, and expects to finalize the fair value of the acquired assets within one year of the acquisition date. The Company assigned the preliminary fair value of the consideration paid of $155,000 to domain name intangible assets that are amortized over an estimated useful life of four years. AgingTopic had not yet generated revenues prior to the time of acquisition.

Note 5: Intangible assets

The following table represents the balances of intangible assets as of September 30, 2025, and December 31, 2024;

	September 30, 2025			December 31, 2024
Website Domains	$	155,000		$	155,000

Total Intangible assets		155,000			155,000

Accumulated Amortization – website domains		(29,580	)		(3,229	)
Net intangible assets	$	125,420		$	151,771

On December 6, 2024, the Company closed on its acquisition of the AgingTopic Business and allocated the entire $155,000 purchase price to domain name assets with an estimated life of 4 years.

The following is an amortization analysis of the annual amortization of intangible assets on a fiscal year basis as of September 30, 2025:

For the year ended December 31,	Amount
2025 (3 months remaining)	$	12,399
2026		38,750
2027		38,750
2028		35,521
2029 and thereafter		-
Total remaining intangibles amortization		125,420

The Company recorded amortization expense of $9,688 and $26,351 for the three and nine months ended September 30, 2025.

Table of Contents

Note 6: Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following at September 30, 2025, and December 31, 2024:

	September 30,		December 31,
	2025		2024
Trade accounts payable	$	3,937,173	$	3,677,455
Accrued payroll and payroll taxes		364,437		489,606
Total accounts payable and accrued liabilities	$	4,301,610	$	4,167,061

Note 7: Right to Use Assets and Lease Liabilities – Operating Leases

The Company had operating leases for its clinics for which the Company is currently in negotiations with the Lessors to settle the remaining amounts owed after closing the clinic facilities. As of September 30, 2025, the Company had impaired all balances of the related right to use assets.

Operating lease liabilities are summarized below:

	September 30, 2025			December 31, 2024
Lease liability	$	99,477		$	99,477
Less: current portion		(99,477	)		(99,477	)
Lease liability, non-current	$	-		$	-

As a result of closing the facilities, the Company has made no further lease payments during the year ending December 31, 2024, or the nine months ending September 30, 2025. As of September 30, 2025, the Company has either settled amounts owed or entered into default judgements for all leases except for the office lease, noted in the above table, which we believe is nominal. For all leases for which a legal settlement has been entered into, all amounts have been reclassified to legal settlements as of September 30, 2025. See Note 15 for further details.

Note 8: SBA Loan Payable

PPP Loan Conversion to SBA Loan

During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration (the “SBA”). On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the “PPP Loan”). The PPP Loan bears interest at the rate of 1% per year.

On July 12, 2023, the Company received confirmation of a payment plan arrangement from the SBA for total principal and interest due on the loan of $467,117. Pursuant to this payment plan, the Company agreed to pay a minimum of $2,595 each month until the loan is paid in full in July 2028. The Company will amortize the balance due on the loan including interest at the original PPP loan rate of 1% per annum; a gain on restructure of debt in the amount of $40,622 was recorded on this transaction during the year ended December 31, 2023, and the balance of the loan was recorded at the amount of $433,343 representing the net cash flows discounted at 1%. During the nine months ended September 30, 2025, the Company made principal payments of $20,130 on this loan and recorded interest in the amount of $2,901.

Note 9: Notes Payable

The following table summarizes the outstanding notes payable as of September 30, 2025, and December 31, 2024:

	September 30, 2025		December 31, 2024
Kishon Note	$	431,666	$	431,666
Finnegan Note 1		-		51,765
Finnegan Note 2		-		32,353
Finnegan Note 3		-		32,353
2025 Bridge Notes		210,000		-
Total Notes Payable		641,666		548,137

Current Portion		641,666		548,137
Long-term portion	$	-	$	-

Table of Contents

Kishon Note

On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Kishon Agreement”) with Kishon Investments, LLC (“Kishon”) with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “Kishon Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “Kishon Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “Kishon Warrants”). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793.

The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022, and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492.

During the year ended December 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the Kishon Note. During the year ended December 31, 2024, as a result of the variable price of the conversion feature, the Company recorded an initial derivative liability of $100,551 upon bifurcating the conversion feature pursuant to ASC815. See Note 11 to these financials for further discussion.

At September 30, 2025, principal and interest in the amount of $431,666 and $224,939, respectively, were due on the Kishon Note. At December 31, 2024, principal and interest in the amount of $431,666 and $166,823, respectively, were due on the Kishon Note. This note was in default at September 30, 2025.

Finnegan Note 1

On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the “Finnegan Note 1”). Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to Finnegan Note 1.

Finnegan Note 2

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the “Finnegan Note 2”). Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2.

Table of Contents

Finnegan Note 3

On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the “Finnegan Note 3”) to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the “Finnegans”). Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3.

On April 24, 2025, the Company entered into an Obligation Exchange Agreement with Finnegan whereby Finnegan agreed to settle the above notes, accrued interest and other obligations in consideration of the issuance of 75,000 shares of restricted common stock for each of the holders. As a result of the exchange the Company recorded a gain on settlement of liabilities of $303,638.

At September 30, 2025, all principal and accrued interest were fully satisfied and retired on these notes. At December 31, 2024, principal and accrued interest in the amount of $105,883 and $44,957, respectively, were due on these notes.

2025 Bridge Notes

On May 6, 2025, the Company entered into a short term note payable agreement with one of its investors and received cash proceeds of $25,000. The note is bears interest at 10% per annum and matures 10 days after issuance, May 17, 2025. In the event of default, the Company is required to pay 120% of the principal balance. This note has been exchanged for a 12 month note without penalty with an original issue discount of 5%, bears no interest on the unpaid principal balance of Notes unless and until an event of default has occurred and in the event of default, accrue interest at a rate equal to 15% or, if less, the highest amount permitted by law payable from and after the occurrence and during the continuance of any event of default until the event of default is cured, and have a twelve month term. The total face value of the Notes in aggregate is $26,250. An event of default includes, among others, failure to pay the debt on maturity date, breach of representation or warranty, occurrence of a material adverse event, failure to comply with reporting obligations with the Securities and Exchange Commission, or the loss of trading of Company’s common stock on the OTC Markets. In the event of default, the Notes are convertible at the election of the noteholder, into common stock of the Company at the average VWAP price for the preceding five business days.

On May 19, 2025, the Company entered into Senior Secured 5% Original Issue Discount Promissory Notes with three of its institutional investors for gross proceeds of $75,000. (“Notes”). The Notes are issued with an original issue discount (OID) of 5%, bear no interest on the unpaid principal balance of Notes unless and until an event of default has occurred and in the event of default, accrue interest at a rate equal to 15% or, if less, the highest amount permitted by law payable from and after the occurrence and during the continuance of any event of default until the event of default is cured, and have a twelve month term. The total face value of the Notes in aggregate is $78,750. An event of default includes, among others, failure to pay the debt on maturity date, breach of representation or warranty, occurrence of a material adverse event, failure to comply with reporting obligations with the Securities and Exchange Commission, or the loss of trading of Company’s common stock on the OTC Markets. In the event of default, the Notes are convertible at the election of the noteholder, into common stock of the Company at the average VWAP price for the preceding five business days.

On July 21, 2025, the Company entered into Senior Secured 5% Original Issue Discount Promissory Notes with two of its institutional investors for gross proceeds of $100,000. (“Notes”). The Notes are issued with an original issue discount (OID) of 5%, bear no interest on the unpaid principal balance of Notes unless and until an event of default has occurred and in the event of default, accrue interest at a rate equal to 15% or, if less, the highest amount permitted by law payable from and after the occurrence and during the continuance of any event of default until the event of default is cured, and have a twelve month term. The total face value of the Notes in aggregate is $105,000. An event of default includes, among others, failure to pay the debt on maturity date, breach of representation or warranty, occurrence of a material adverse event, failure to comply with reporting obligations with the Securities and Exchange Commission, or the loss of trading of Company’s common stock on the OTC Markets. In the event of default, the Notes are convertible at the election of the noteholder, into common stock of the Company at the average VWAP price for the preceding five business days.

Aggregate interest expense on the notes payable was $23,229 and $32,416 for the three months ended September 30, 2025 and 2024 respectively. Aggregate interest expense on the notes payable was $65,815 and $140,643 for the nine months ended September 30, 2025 and 2024. Accrued interest on notes payable were $230,773 and $211,780 at September 30, 2025, and December 31, 2024, respectively.

Table of Contents

Note 10: Notes Payable – Related Parties

The following table summarizes the outstanding related party notes payable as of September 30, 2025, and December 31, 2024;

	September 30, 2025		December 31, 2024
Lindstrom Note	$	-		45,294
Lindstrom Note 2		-		18,750
Notes Payable		-		64,044

Current Portion, net of discount	$	-	$	64,044
Long-term portion, net of discount	$	-	$	-

Lindstrom Note

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, who was the Company’s Chief Legal Officer (the “Lindstrom Note 1”). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1.

Lindstrom Note 2

On November 29, 2022, the Company issued a promissory note (the “Lindstrom Note 2”) in a related party transactions to Jenny Lindstrom, who was the Company’s former Vice President and Chief Legal Officer. The Lindstrom Note 2 has a due date of May 28, 2023, and bears interest at the rate of 10% per annum which will accrue from the date of the note. Following an event of default as defined, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 2, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 2. In addition, Lindstrom received a five-year warrant to purchase 750 shares of the Company’s common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. This warrant has been cancelled in conjunction with the satisfaction of the notes.

On April 24, 2025, the Company entered into an Obligation Exchange Agreement with Lindstrom whereby Lindstrom agreed to settle the above notes, accrued interest and other obligations in consideration of the issuance of 75,000 shares of restricted common stock for each of the holders. As a result of the exchange the Company recorded a gain on settlement of liabilities of $249,765.

At September 30, 2025, all principal and accrued interest were fully satisfied and retired on these notes. At December 31, 2024, there was principal and interest in the aggregate amount of $64,044 and $22,548, respectively, due on these notes.

Aggregate interest expense on the notes payable – related parties was $0 and $10,587 for the three months ended September 30, 2025 and 2024, respectively. Aggregate interest expense on the notes payable – related parties was $2,297 and $26,133 for the nine months ended September 30, 2025 and 2024, respectively. Accrued interest on notes payable – related parties were $0 and $22,547 at September 30, 2025, and December 31, 2024, respectively.

Table of Contents

Note 11: Derivative Liabilities

Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The derivative components of these notes are valued at issuance, at conversion, at restructuring, and at each period end.

Derivative liability activity for the nine months ended September 30, 2025, is summarized in the table below:

December 31, 2024	$	4,685,675
Gain on revaluation		(3,513,655	)
September 30, 2025	$	1,172,020

The following assumptions were used for the valuation of the derivative liability associated with this obligation:

	●	The stock price on the date of valuation represents the fair market value of the stock

	●	The notes convert with variable conversion prices based on the percentages of the lowest trades over the prior 20 trading days

	●	The holder would automatically convert the note immediately (based on ownership or trading volume limitations) if the registration were effective and the Company was not in default

Note 12: Series A Preferred Stock

On October 28, 2024, the Company filed a Certificate of Designation, Preferences and Rights of the Series A Preferred Stock with the Nevada Secretary of State (the “Certificate of Designation”). The Company authorized 3,000,000 shares of Series A Preferred Stock, par value $0.01 per share. Each share of Series A Preferred Stock has a stated value equal to $25. The Series A Shares may be converted into shares of common stock by dividing the stated value by $4.00 (the “Conversion Price”). The Series A Shares may be converted at the option of the holder at any time, or mandatorily by the Company if certain conditions set forth in the Certificate of Designation are met. Unless prior conversion has occurred, shares of Series A Preferred Stock will be redeemed by the Company, using Common Stock, or cash, 1/36^th of the remaining amounts monthly beginning in January 2025. The cash redemption shall be at 105% of the original price of Series A Preferred Stock (as adjusted) whereas Common Stock redemption shall be at a 10% discount to the average of the five lowest closing prices over a 30-trading day period. The Company intends to accrue the redemption shares monthly and issue any shares to be used thereunder quarterly to reduce its expense.

Holders of shares of the Series A Preferred Stock are not entitled to receive any dividends, and the security bears no interest.

The Series A Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Company, (i) senior to all classes or series of the Company’s Common Stock, and to all other equity securities issued by the Company; and (ii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or preferred stock) of the Company and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others in) existing subsidiaries of the Company.

In addition to any other rights provided by law, except where the vote or written consent of the holders of a greater number of shares is required by law or by another provision of the Articles of Incorporation, without first obtaining the affirmative vote at a meeting duly called for such purpose or the written consent without a meeting of the majority of the outstanding Series A Preferred Stock, voting together as a single class, the Company shall not: (a) amend or repeal any provision of, or add any provision to, its Articles of Incorporation or bylaws, or file any certificate of designations or certificate of amendment, if such action would adversely alter or change in any respect the preferences, rights, privileges or powers, or restrictions provided for the benefit, of the Series A Preferred Stock, regardless of whether any such action shall be by means of amendment to the Articles of Incorporation or by merger, consolidation or otherwise; or (b) without limiting the provisions of the Certificate of Designation, circumvent a right of the Series A Preferred Stock.

As a result of the mandatory redemption features requiring the Company to repay the Series A in either cash or shares of Common Stock of the Company, under ASC 480, the Company is required to record the full redemption value of the Series A preferred shares as a liability on the accompanying balance sheet. The Company has recorded the redemption value based on the 10% premium required if the Company were to repay in shares of Common Stock due to the current expected cash flows of the Company.

During the nine months ended September 30, 2025, the Company issued 5,000 shares of Series A preferred stock in exchange for $125,000 in cash proceeds.

During the nine months ended September 30, 2025, the Company redeemed 34,658 shares of Series A preferred for 3,794,802 shares of common stock with a fair value of $1,604,399, which resulted in a loss on settlement of $643,666. During the three and nine months ended September 30, 2025, the Company recognized $277,681 and $907,007, respectively, in interest expense related to the accretion of the Series A preferred shares based on the change in fair value.

Table of Contents

The following table provides the maturities of Series A preferred stock redemptions at September 30, 2025:

	Series A Preferred Stock
2025	$	4,240,569
2026		5,206,648
2027		5,206,648
2028		5,347
2029 and thereafter		-
Total future undiscounted redemption payments		14,659,212
Less: Interest		(1,261,491	)
Present value of redemption payments		13,397,721
Current portion		(7,030,279	)
Long term portion	$	6,367,442

Note 13: Stockholders’ Equity (Deficit)

Common Stock

The Company has authorized 500,000,000 shares of common stock, par value $0.01; 15,093,055 were issued and outstanding at September 30, 2025.

During the nine months ended September 30, 2025, the Company issued 161,042 shares of common stock for dividends payable on its Series X Preferred Stock as discussed in further detail below. The price per share used in determining the number of shares issued was the stock price on the 15^th day of each month to determine the number of shares issuable.

During the nine months ended September 30, 2025, the Company issued 3,794,755 shares of its restricted common stock for the redemption of Series A shares as discussed in further detail above in Note 12.

During the nine months ended September 30, 2025, the Company recorded stock-based compensation of $12,500 related to equity awards issued in prior periods. As of September 30, 2025, the Company expects to record additional compensation expense of $0 related to unvested awards.

During the nine months ended September 30, 2025, the Company issued 1,225,000 shares to consultants for services performed with a fair value of $252,150 with was recorded as stock-based compensation.

During the nine months ended September 30, 2025, the Company entered into Obligation Exchange Agreements with two of its creditors, Finnegan and Lindstrom as discussed above in Notes 9 and 10. The agreements call for the cancellation of notes, accrued interest and other obligations in consideration of the issuance of 75,000 shares of restricted common stock for each of the holders, which resulted in an aggregate gain on the settlement of liabilities of $553,403.

Preferred Stock

We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 3,000,000 shares of Series A Preferred (see Note 12), 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred, 140,000 shares of Series F Preferred, and 42,103 shares as Series X Preferred Stock.

Series D Preferred Stock

The Series D Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series D ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu to the Series C Preferred Stock. Each holder of our Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D preferred Stock held by such holder. The Company had zero and 25,000 shares of Series D Preferred Stock outstanding at September 30, 2025 and December 31, 2024.

During the nine months ended September 30, 2025, into Obligation Exchange Agreements with Lindstrom whereby the outstanding Series D Preferred Stock and all accrued dividends were exchanged for shares of Company common stock.

The Company accrued dividends in the amount of $388 on the Series D Preferred Stock for the nine months ended September 30, 2025. As of September 30, 2025 and December 31, 2024, the Company had $0 and $5,049 in accrued dividends on the Series D Preferred Stock, respectively.

Table of Contents

Series F Preferred Stock

The number of shares of Series F Preferred Stock designated is 140,000 and each share of Series F Preferred Stock has par value of $0.01, a liquidation preference of $1,000 and PIK dividends at 12%. The Series F Preferred Stock will rank senior to the Corporation’s Common Stock and on parity with all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank on parity with the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Corporation; and (iii) junior to all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank senior to the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Company.

Holders of shares of the Series F Preferred Stock are entitled to receive payment-in-kind dividends payable only in additional shares of Series F Preferred Stock (“PIK Dividends”) at rate of 12% per annum.

The Series F Preferred Stock will be convertible into common stock of the Company upon the listing of the Company’s stock on any of the following trading markets: the NYSE, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, or the Nasdaq Global Select Market. The conversion price will be calculated as 65% of the volume-weighted average price of the Company’s common stock on the conversion date. The number of shares issuable upon conversion will be calculated as the liquidation preference of the Series F Preferred stock plus any accrued but unpaid dividends divided by the conversion price.

There are no shares of Series F shares outstanding as of December 31, 2024, or September 30, 2025.

Series X Preferred Stock

The Company has 42,103 and 19,703 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of September 30, 2025, and December 31, 2024, respectively. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Beginning in October 2024, the Company elected to use the closing stock price on the 15^th of each month. Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders.

During the nine months ended September 30, 2025, the Company issued 2,400 shares of Series X Preferred Stock to the newly elected director of the Company for compensation in lieu of services in the amount of $60,000.

During the nine months ended September 30, 2025, the Company issued 20,000 shares of Series X Preferred Stock to an institutional investor and consultant for compensation in lieu of services in the amount of $500,000.

The Company accrued dividends in the amount of $42,609 on the Series X Preferred Stock for the nine months ended September 30, 2025. As of September 30, 2025, and December 31, 2024 the Company had $0 in accrued dividends on the Series X Preferred Stock.

Warrants

The Company has announced that it intends to cancel all outstanding warrants, and certain language to complete this has been added to all documents related to the conversion of outstanding debts, notes, accounts payable and other senior securities. The following table summarizes the warrants outstanding on September 30, 2025, and the related prices for the warrants to purchase shares of the Company’s common stock:

						Weighted				Weighted
				Weighted		average				average
				average		exercise				exercise
Range of		Number of		remaining		price of		Number of		price of
exercise		warrants		contractual		outstanding		warrants		exercisable
prices		outstanding		life (years)		warrants		exercisable		warrants
$	25.00		5,556		1.61		25.00		5,556		25.00
$	37.50		32,000		1.25		37.50		32,000		37.50
			37,556		1.30	$	35.65		37,556	$	35.65

Table of Contents

The following table summarizes the transactions involving options to purchase shares of the Company’s common stock:

	Shares			Weighted- Average Exercise Price ($)
Outstanding at December 31, 2024		40,767		$	35.13
Granted		-		$	-
Cancelled		(3,211	)	$	(29.09	)
Exercised		-		$	-
Outstanding at September 30, 2025		37,556		$	35.65

At September 30, 2025, there was no intrinsic value on the issued or vested warrants.

Note 14: Fair Value of Financial Instruments

The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at September 30, 2025, and December 31, 2024.

	September 30, 2025
	Level 1		Level 2		Level 3		Total
Liabilities
Derivative liabilities	$	-	$	-	$	1,172,020	$	1,172,020

	December 31, 2024
	Level 1		Level 2		Level 3		Total
Liabilities
Derivative liabilities	$	-	$	-	$	4,685,675	$	4,685,675

Table of Contents

Note 15: Commitments and Contingencies

Legal

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

The Company has a number of legal situations involved with the winding down of its clinic’s business activities. These include claims regarding certain construction contracts and cancellation of leases as noted below:

Nordhaus Clinic

On November 1, 2020, we entered into an agreement to open a clinic in Minneapolis, Minnesota. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $511,000. On November 6, 2023, the Company received a termination notice from the landlord indicating the lease had been terminated. No additional claims have been received from the landlord, and the Company believes no additional amounts are owed.

Egan Clinic a.k.a. Vikings

On October 14, 2021, we entered into an agreement to open a clinic in Eagan, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 96 months. Fixed rent payments under the initial term are approximately $767,000. A Summary Judgment was granted on December 4, 2023, in the amount of $488,491, and the entry of final judgment was entered on December 15, 2023, and the Company has released the property back to the leaseholder.

St. Paul Clinic a.k.a. The Grove

On August 31, 2021, we entered into an agreement to open a clinic in St. Paul, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 114 months. Fixed rent payments under the initial term are approximately $1,153,000. A stipulation for Judgment was filed on December 21, 2023, in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics’ liens, and $64,600 in attorneys’ fees. Final entry of judgment by the Court was entered against the Company on January 19, 2024, and the Company has released the property back to the leaseholder.

St. Louis Park Clinic a.k.a. Excelsior & Grand

On May 24, 2021, we entered into an agreement to open a clinic in St. Louis Park, Minnesota, which began operations in the third quarter of 2021. The initial lease term is seven years. Fixed rent payments under the initial term are approximately $673,000. The Company agreed to and executed a Confession of Judgment in the amount of $425,350 on April 2, 2024, and has released the property back to the leaseholder. We received the fully executed and recorded judgement on April 10, 2024.

Eden Prairie Clinic a.k.a. TP Elevate

On June 8, 2021, we entered into an agreement to open a clinic in Eden Prairie, Minnesota, which began operation in the third quarter of 2021. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $620,000. The Company has surrendered possession of the property and is currently in negotiations for the amounts owed and is in the process of settling the remaining amounts owed.

Maple Grove Clinic a.k.a. Arbor Lakes

On October 8, 2021, we entered into an agreement to open a clinic in Maple Grove, Minnesota which began operation in the fourth quarter of 2021. The initial lease term is for 108 months. Fixed rent payments under the initial term are approximately $1,153,127. On October 22, 2022, the Company entered into a settlement agreement with the leaseholder for $219,576 and the Company released the property back to the leaseholder.

Radiant Clinic a.k.a. LMC Welton

On September 9, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 90 months. Fixed rent payments under the initial term are approximately $782,000. As of April 10, 2024, the Company has settled the amounts owed to the leaseholder and full resolution of all liens for approximately $530,000 and the Company has released the property back to the leaseholder.

Table of Contents

Quincy Clinic a.k.a. 1776 Curtis

On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder. The owner of the Quincy Clinic property filed before the same court, an action against the Company seeking to modify the final settlement for an additional $1,250,000, including $350,000 which represent amounts paid to the contractor who was performing the build out, who had filed liens on the property. As of August 8th, 2025, we settled this matter by providing an additional judgment in the amount of $500,000.

The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

LOCATION	PROPERTY NAME	ORIGINAL OBLIGATION		SETTLEMENT AMOUNT		DATE OF AWARD	INTEREST RATE			INTEREST ACCRUED ON SETTLEMENT		TOTAL SETTLEMENT OBLIGATION		TYPE OF SETTLEMENT
WAYZETTA, MN	WAZETTA BAY	$	407,000	$	25,000	NA		-			-	$	25,000	CASH PAYMENT OBLIGATION
EAGAN, MN	VIKINGS	$	767,000	$	488,491	12/7/2023		10	%	$	88,731	$	577,222	DEFAULT JUDGEMENT
ST. LOUIS PARK, MN	EXCELSIOR	$	673,000	$	425,350	5/22/2024		10	%	$	57,801	$	483,151	DEFAULT JUDGEMENT
ST. PAUL, MN	CONTINENTAL 560	$	1,153,000	$	415,606	1/22/2024		10	%	$	70,254	$	485,860	DEFAULT JUDGEMENT
MAPLE GROVE, MN	BUTTNICK	$	1,153,127	$	219,000	10/3/2022		10	%	$	65,580	$	284,580	SETTLEMENT AGREEMENT
DENVER, CO	RADIANT	$	782,000	$	530,557			-			-	$	530,557	DISMISSED
DENVER, CO	QUINCY(1)	$	1,079,000	$	848,764	11/14/2023		12	%		87,699	$	936,463	DEFAULT JUDGEMENT
	TOTAL	$	6,014,127	$	2,952,768					$	370,066	$	3,322,834

Administrative offices

On June 24, 2021, we entered into an agreement to open an administrative office in St. Louis Park, Minnesota. The initial lease term is 2.5 years. Fixed rent payments under the initial term are approximately $244,000. We have not received any claims as to the obligations under this sublease agreement and the business from which we were renting has not responded to communications from our attorneys who have attempted to establish a formal settlement agreement since we have abandoned the location more than a year ago. We have received no communication from the landlord and we do not believe any further obligations exist.

During the three and nine months ending September 30, 2025, the Company recorded interest expense of $58,619 and $156,159, respectively related to the above settlements based on the statutory rates of the courts in the respective locations. There was no interest expense recorded for the three and nine months ended September 30, 2024.

Note 16: Income Taxes

Deferred income taxes result from the temporary differences primarily attributable to amortization of intangible assets and debt discount and an accumulation of net operating loss carryforwards for income tax purposes with a valuation allowance against the carryforwards for book purposes.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Included in deferred tax assets are Federal and State net operating loss carryforwards of approximately $63.1 million and $17.7 million, respectively, which will expire through 2040. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Due to significant changes in the Company’s ownership, the Company’s future use of its existing net operating losses may be limited.

Table of Contents

For the nine months ended September 30, 2025, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	For the Nine Months Ended September 30,
	2025
Expected tax at statutory rates
Federal	$	34,000		21	%
State		(16,000	)	(10	)%
Permanent Differences		(1,000	)	(1	)%
Temporary difference for derivative gain		(738,000	)	(461	)%
Temporary difference for stock compensation		173,000		108	%
Other		70,000		44	%
Current Year Change in Valuation Allowance
Federal		990,000		618	%
State		(512,000	)	(320	)%
Income tax expense	$	-		0	%

Deferred income taxes reflect the tax impact of temporary differences between the amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations.

Deferred income taxes include the net tax effects of net operating loss (NOL) carryforwards and the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of September 30, 2025, and December 31, 2024, significant components of the Company’s deferred tax assets are as follows:

	As of
	September 30, 2025			December 31, 2024
Deferred Tax Assets (Liabilities):
Accrued payroll	$	141,000		$	141,000
ASC842-ROU (Liability)		822,000			822,000
Loss from derivatives		(203,000	)		(869,000	)
Stock based compensation		(460,000	)		(304,000	)
Depreciation		3,000			3,000
Net operating loss		12,942,000			12,462,000
Net deferred tax assets (liabilities)		13,245,000			12,255,000
Valuation allowance		(13,245,000	)		(12,255,000	)
Net deferred tax assets (liabilities)	$	-		$	-

Note 17: Subsequent Events

On October 31, 2025 the Company entered into a Senior Secured 10% Original Issue Discount Convertible Promissory Note (the “2025 Bridge Note”) financing agreement with one of our historical institutional investors, C/M Capital Master Fund, L.P. for a potential total funding of $1 million, with an initial funding with net proceeds of $250,000. Under the terms of the 18 month note the Company is obligated to repay a total of $275,000 as the note includes a 10% original issue discount. The note bears no interest unless in default and may be converted into common stock of the Company at $0.15 per share, subject to certain adjustments. The obligations under the 2025 Bridge Note are guaranteed by the subsidiaries of the Company and included a pledge of the securities the Company’s subsidiaries and first priority senior security interest in all the Company’s assets.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References to the “Company,” “Mitesco, Inc.,” “our,” “us” or “we” refer to Mitesco, Inc. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited interim financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

Company Overview

Current Business Operations

We are a holding company seeking to provide products, services and technology.

The Vero Technology Ventures (VTV) subsidiary is actively reviewing potential early-stage cloud computing solution vendors and is developing its own artificial intelligence (A.I.) based application set. VTV is currently involved with the formation of a new software development project aimed at applying artificial intelligence (A.I.) to the sales process for various businesses including residential real estate using cloud computing based software. This initial effort dubbed “Robo Agent”, is expected to be available for initial users in Q4 of FY2025. Later versions may include similar functionality focused on other markets, generally in a “business to consumer” (B2C) selling situation.

Table of Contents

There are several other projects in evaluation, generally aimed at software that would operate on a cloud computing platform such as that which the Company has in its Centcore Data Center.

FY2024 Debt Restructuring

From FY2021 until late FY2022 the Company invested in an operating subsidiary, The Good Clinic, which was developing a series of primary care healthcare facilities. In late FY2022, as a result of a lack of adequate revenues and limited funding, it ceased operations. As of June 30, 2024, the Company had over $30 million in senior securities, notes and accounts payable related to that discontinued operation. In order to clear those obligations management began a restructuring which involved negotiations to reduce the overall debt, converting certain accredited institutional investors into a newly created Series A Amortizing Preferred stock (“Series A Preferred”), and all others into restricted common stock using a price per share of $4.00.

As of the date of this filing it has converted over $25 million of its obligations, representing over $20 million of its senior securities, and over $2 million of notes and accounts payable, into 2,478,179 of restricted Common Stock, and 566,085 shares of Series A Preferred stock. The Series A Preferred stock is held by six (6) accredited institutional investors, while over 40 holders of obligations of the Company elected to receive common stock using the $4 per share valuation.

Included in the above totals, effective December 31, 2024, the Company has entered into Obligation Exchange Agreements pursuant to which it has converted $580,132, including $32,132 of principal and interest, of its 2024 Bridge Notes into Series A Preferred shares, which resulted in the issuance of 23,206 shares of Series A Preferred shares to three (3) of its institutional investor. This extinguishes $580,132 of its short-term debt. As of the date of this filing all FY2024 bridge notes have been extinguished. Further, during January 2025 the Company issued 4,000 shares of its Series A Preferred shares in consideration of an investment of $100,000 by three (3) of its institutional investors.

As part of the restructuring, the Company agreed to register shares of Common Stock issued and to be issued to Series A Preferred Stockholders.

Comparison of the Three Months Ended September 30, 2025, and 2024.

Revenues

We had revenues of $3,000 for the three months ended September 30, 2025, compared to $23,500 in the comparable period. The revenues were related to our newly formed subsidiary Centcore, LLC. We shifted much of our limited resources to our new software projects during Q3 and as a result we saw a reduction in data center revenue.

Operating Expenses

Our total operating expenses for the three months ended September 30, 2025, were $1,014,422. For the comparable period in 2024, the operating expenses were $239,742. The increase is the result of the Company’s focus on establishing the operations of its newly formed subsidiaries as well as development of a software platform in addition to stock-based compensation expense of $812,149 for the three months ended September 30, 2025 compared to $106,250 for the comparable period.

Other Income and Expenses

Interest expense was $386,699 for the three months ended September 30, 2025, compared to $50,979 for the comparable period in 2024. The increase was a result of the Series A preferred shares accretion and interest on the outstanding legal settlements.

Interest expense – related parties was $0 for the three months ended September 30, 2025, compared to $10,587 in the prior period. The decrease was a result of reduced debt balances in the current period.

Table of Contents

During the three months ended September 30, 2024, we recorded a gain on settlement of operating lease liabilities of $636,485. There were no comparable transactions in the current period.

During the three months ended September 30, 2025, we recorded a loss on settlement of legal settlement of $500,000. There were no comparable transactions in the prior period.

During the three months ended September 30, 2024, we recorded a gain on settlement of notes payable of $693,768. There were no comparable transactions in the current period.

During the three months ended September 30, 2024, we recorded a gain on settlement of accounts payable of $1,024,583. There were no comparable transactions in the current period.

During the three months ended September 30, 2025, we recorded a loss on revaluation of derivative liabilities of $917,212. There were no comparable transactions in the prior period.

During the three months ended September 30, 2025, we recorded a loss on revaluation of Series A preferred shares of $387,638. There were no comparable transactions in the prior period.

Comparison of the Nine Months Ended September 30, 2025, and 2024.

Revenues

We had revenues of $38,700 for the nine months ended September 30, 2025, compared to $29,500 in the comparable period. The revenues were related to our newly formed subsidiary Centcore, LLC.

Operating Expenses

Our total operating expenses for the nine months ended September 30, 2025, were $1,668,862. For the comparable period in 2024, the operating expenses were $721,095. The increase is the result of the Company’s focus on establishing the operations of its newly formed subsidiaries as well as development of a software platform, in addition to stock-based compensation expense of $824,649 for the nine months ended September 30, 2025 compared to $388,250 for the comparable period.

Other Income and Expenses

Interest expense was $1,137,355 for the nine months ended September 30, 2025, compared to $159,206 for the comparable period in 2024. The increase was a result of the Series A preferred shares accretion and interest on the outstand legal settlements.

Interest expense – related parties was $2,297 for the nine months ended September 30, 2025, compared to $26,133 in the prior period. The decrease was a result of reduced debt balances in the current period.

During the nine months ended September 30, 2025, we recorded a gain on settlement of liabilities of $562,793. During the nine months ended September 30, 2024, we recorded a gain on settlement of accounts payable of $1,024,583.

During the nine months ended September 30, 2025, we recorded a loss on legal settlement of $500,000. There were no comparable transactions in the prior period.

During the nine months ended September 30, 2025, we recorded a gain on revaluation of derivative liabilities of $3,513,655. There were no comparable transactions in the prior period.

During the nine months ended September 30, 2025, we recorded a loss on revaluation of Series A preferred shares of $646,653. There were no comparable transactions in the prior period.

Liquidity and Capital Resources

To date, we have not generated sufficient revenue from operations to support our operations. We have financed our operations through the sale of equity securities and short-term borrowings. As of November 13, 2025, we had cash of approximately $55,000 compared to cash of approximately $300 as of September 30, 2025. This was as a result of our latest financing using the 2025 Bridge Notes (see subsequent events). Our Company’s recurring losses from operations and negative cash flows from operations and our need to raise additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern.

Net cash used in operating activities was $308,963 for the nine months ended September 30, 2025. This is the result of establishing the operations of the Company’s newly formed subsidiaries. Cash used in operations for the nine months ended September 30, 2024, was $399,775.

Table of Contents

The Company had no investing activities for the nine months ended September 30, 2025 and 2024.

Net cash provided by financing activities for the nine months ended September 30, 2025, was $305,882, compared to $428,759 for the nine months ended September 30, 2024. Cash provided by financing activities was the result of cash proceeds from sales of Series A preferred shares of $125,000 and cash proceeds from notes payable of $200,000, offset by the repayment of principal on the SBA loan in the amount of $19,118.

On October 31, 2025 the Company entered into a Senior Secured 10% Original Issue Discount Convertible Promissory Note (the “2025 Bridge Note”) financing agreement with one of our historical institutional investors, C/M Capital Master Fund, L.P. for a potential total funding of $1 million, with an initial funding with net proceeds of $250,000. Under the terms of the 18 month note the Company is obligated to repay a total of $275,000 as the note includes a 10% original issue discount. The note bears no interest unless in default and may be converted into common stock of the Company at $0.15 per share, subject to certain adjustments. The 2025 Bridge Notes may be prepaid at 110% of the outstanding principal amount owed at the time of repayment. The obligations under the 2025 Bridge Note are guaranteed by the subsidiaries of the Company and included a pledge of the securities the Company’s subsidiaries and first priority senior security interest in all the Company’s assets.

At September 30, 2025, we had the following current liabilities which are payable in cash: Accounts payable and accrued liabilities of approximately $4.3 million; notes payable of approximately $0.6 million; SBA Loan Payable of approximately $0.4 million; legal settlements of approximately $3.3 million; accrued interest payable of approximately $0.4 million; and other current liabilities of approximately $0.2 million and royalty payable of approximately $0.2 million. We also have the following liabilities which are payable in stock: derivative liabilities of approximately $1.2 million and Series A Preferred Stock liability of approximately $7 million.

The Series A Preferred Stock are accounted for as a liability as a result of the mandatory redemption features requiring the Company to repay the Series A in either cash or shares of Common Stock of the Company, under ASC 480, the Company is required to record the full redemption value of the Series A preferred shares as a liability. The Company has recorded the redemption value based on the 10% premium required if the Company were to repay in shares of Common Stock due to the current expected cash flows of the Company.

The Company has relationships with a number of consultants who are assisting in the creation of the new business units. It is anticipated that this approach will continue indefinitely as it does not desire to create the overhead associated with a large employment force.

The following table summarizes the status of our property-related settlements as noted above and the total settlement amounts as of the date of the filing:

LOCATION	PROPERTY NAME	ORIGINAL OBLIGATION		SETTLEMENT AMOUNT		DATE OF AWARD	INTEREST RATE			INTEREST ACCRUED ON SETTLEMENT(1)		TOTAL SETTLEMENT OBLIGATION		TYPE OF SETTLEMENT
WAYZETTA, MN	WAZETTA BAY	$	407,000	$	25,000	NA		-			-	$	25,000	CASH PAYMENT OBLIGATION
EAGAN, MN	VIKINGS	$	767,000	$	488,491	12/7/2023		10	%	$	88,731	$	577,222	DEFAULT JUDGEMENT
ST. LOUIS PARK, MN	EXCELSIOR	$	673,000	$	425,350	5/22/2024		10	%	$	57,801	$	483,151	DEFAULT JUDGEMENT
ST. PAUL, MN	CONTINENTAL 560	$	1,153,000	$	415,606	1/22/2024		10	%	$	70,254	$	485,860	DEFAULT JUDGEMENT
MAPLE GROVE, MN	BUTTNICK	$	1,153,127	$	219,000	10/3/2022		10	%	$	65,580	$	284,580	SETTLEMENT AGREEMENT
DENVER, CO	RADIANT	$	782,000	$	530,557			-			-	$	530,557	DISMISSED
DENVER, CO	QUINCY	$	1,079,000	$	848,764	11/14/2023		12	%		87,699	$	936,463	DEFAULT JUDGEMENT
	TOTAL	$	6,014,127	$	2,952,768					$	370,066	$	3,322,834

Note (1): accrued interest has been calculated through September 30, 2025.

Table of Contents

Critical Accounting Estimates

Management uses various estimates and assumptions in preparing our financial statements in accordance with generally accepted accounting principles. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Accounting estimates that are the most important to the presentation of our results of operations and financial condition, and which require the greatest use of judgment by management, are designated as our critical accounting estimates. We have the following critical accounting estimates:

●

Estimates and assumptions used in the valuation of derivative liabilities: Management utilizes a lattice model to estimate the fair value of derivative liabilities. The model includes subjective assumptions that can materially affect the fair value estimates.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

(a)

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such an evaluation, the Company’s management has identified what it believes are material weaknesses in the Company’s disclosure controls and procedures and concluded that we did not have effective disclosure controls and procedures.

The deficiencies in our disclosure controls and procedures included (i) lack of segregation of duties and (ii) lack of sufficient resources to ensure that information required to be disclosed by the Company in the reports that the Company files or submits to the SEC are recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms.

The Company intends to take corrective action to ensure that information required to be disclosed by the Company pursuant to the reports that the Company files or submits to the SEC is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

(b)

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the three months ended September 30, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company has a number of legal situations involved with the winding down of its clinic business activities. These include claims regarding certain construction contracts and cancellation of leases as noted below:

LOCATION	PROPERTY NAME	ORIGINAL OBLIGATION		SETTLEMENT AMOUNT		DATE OF AWARD	INTEREST RATE			INTEREST ACCRUED ON SETTLEMENT(1)		TOTAL SETTLEMENT OBLIGATION		TYPE OF SETTLEMENT
WAYZETTA, MN	WAZETTA BAY	$	407,000	$	25,000	NA		-			-	$	25,000	CASH PAYMENT OBLIGATION
EAGAN, MN	VIKINGS	$	767,000	$	488,491	12/7/2023		10	%	$	88,731	$	577,222	DEFAULT JUDGEMENT
ST. LOUIS PARK, MN	EXCELSIOR	$	673,000	$	425,350	5/22/2024		10	%	$	57,801	$	483,151	DEFAULT JUDGEMENT
ST. PAUL, MN	CONTINENTAL 560	$	1,153,000	$	415,606	1/22/2024		10	%	$	70,254	$	485,860	DEFAULT JUDGEMENT
MAPLE GROVE, MN	BUTTNICK	$	1,153,127	$	219,000	10/3/2022		10	%	$	65,580	$	284,580	SETTLEMENT AGREEMENT
DENVER, CO	RADIANT	$	782,000	$	530,557			-			-	$	530,557	DISMISSED
DENVER, CO	QUINCY	$	1,079,000	$	848,764	11/14/2023		12	%		87,699	$	936,463	DEFAULT JUDGEMENT
	TOTAL	$	6,014,127	$	2,952,768					$	370,066	$	3,322,834

Note (1): accrued interest has been calculated through September 30, 2025.

Quincy Clinic a.k.a. 1776 Curtis

On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder. The owner of the property has filed before the same court, an action against the Company (Case No. 2022 CV 33173, Division: 409, Consolidated with 2022CV33653) seeking to modify the final settlement for an additional $1,250,000, including $350,000 which represent amounts paid to the contractor who was performing the build out, who had filed liens on the property. As of August 8th, 2025, we settled this matter by providing an additional judgment in the amount of $500,000.

Administrative office

On October 31, 2025 the Company entered into a Senior Secured 10% Original Issue Discount Convertible Promissory Note (the “2025 Bridge Note”) financing agreement with one of our historical institutional investors, C/M Capital Master Fund, L.P. for a potential total funding of $1 million, with an initial funding with net proceeds of $250,000. Under the terms of the 18 month note the Company is obligated to repay a total of $275,000 as the note includes a 10% original issue discount. The note bears no interest unless in default and may be converted into common stock of the Company at $0.15 per share, subject to certain adjustments. The 2025 Bridge Notes may be prepaid at 110% of the outstanding principal amount owed at the time of repayment. The obligations under the 2025 Bridge Note are guaranteed by the subsidiaries of the Company and included a pledge of the securities the Company’s subsidiaries and first priority senior security interest in all the Company’s assets.

Gardner Debt for Equity Agreement and other obligations

The Company entered into a debt-for-equity exchange agreement with Gardner Builders Holdings, LLC (the “Creditor”) on January 7, 2022 (the “Agreement”). Pursuant to the Agreement, the Company issued shares of restricted common stock, par value $0.01 per share, of MITI (the “Restricted Shares”) to the Creditor in exchange for the Company Debt Obligations, as defined below.

The Agreement settled certain accounts payable amounts owed by the Company to the Creditor (the “Accounts Payable Amount”) as well as then upcoming amounts that would become due between the date of the Agreement and April 1, 2022. The Agreement also settled incurred interest and penalties on the amounts due through January 5, 2022, as well as future interest payments on amounts to be incurred in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount was $500,000, the Additional Costs were $294,912 and the conversion price was $12.50. As a result, 63,593 Restricted Shares were authorized to be issued. The Company’s Board of Directors approved the Agreement on January 5, 2022. Much of the amounts claimed by Gardner have been resolved by the settlements with the various leaseholders where Gardner had filed liens. During 2021 and through 2022 a total of $2,305,155 was paid by the Company directly to Gardner for their services. As of the date of this filing the Company is continuing an effort to negotiate a settlement.

Table of Contents

ITEM 1A. RISK FACTORS

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on September 30, 2025. There have been no material changes to the risk factors described in that report.

ITEM 2. SALE OF UNREGISTERED SECURITIES

During the period ending September 30, 2025, the Company made the following issuances of restricted common stock:

Issuance of Restricted Common Stock for Series X Preferred Stock Dividends

During the three months ended September 30, 2025, the Company issued 99,336 shares of common stock for dividends payable on its Series X Preferred Stock

Issuance of Restricted Common Stock for the Redemption of Series A Preferred Stock

On September 30, 2025, the Company issued 2,025,910 shares of its restricted common stock in order to redeem $257,700 of its Series A Preferred stock, effective September 30, 2025.

Issuance of Restricted Common Stock for compensation

During the three months ended September 30, 2025, the Company issued 1,225,000 shares to consultants for services performed with a fair value of $252,150 which was recorded as stock-based compensation.

ITEM 3. DEFAULTS ON SENIOR SECURED SECURITIES

Not Applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

Not Applicable.

Table of Contents

ITEM 6. EXHIBITS

The following exhibits are included with this Quarterly Report on Form 10-Q.

		Form Type	Exhibit Number	Date Filed	Filed Herewith

3.1	Certificate of Incorporation of Trunity Holdings, Inc., dated January 18, 2012.	8-K	10.1	1/31/2012

3.2	Bylaws of Trunity Holdings, Inc., dated January 18, 2012.	8-K	10.2	1/31/2012

3.3	Certificate of Ownership Merging between Trunity Holdings, Inc. and Brain Tree International, Inc. dated January 24, 2012.	10-K	3.3	4/16/2013

3.4	Certificate of Amendment to the Certificate of Incorporation of Trunity Holdings, Inc., dated December 24, 2015.	8-K	3.1(i)	1/06/2016

3.5	Certificate of Designations of Series X Preferred Stock of True Nature Holding, Inc.	8-K	3.6	1/06/2020

3.6	Form of Amended and Restated Certificate of Designations of Series A Preferred Stock of True Nature Holding, Inc.	8-K	3.07	3/13/2020

3.7	Certificate of Amendment of the Certificate of Incorporation of True Nature Holding, Inc. dated April 21, 2020.	10-Q	3.7	8/14/2020

3.8	Certificate of Amendment of Certificate of Incorporation, dated as of November 5, 2020, correcting December 24, 2015, Certificate of Amendment.	10-Q	3.8	11/13/2020

3.9	Bylaws of Mitesco, Inc., as amended, dated November 10, 2020	10-Q	3.9	11/13/2020

3.10	Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.	8-K	3.1	03/26/2021

3.11	Certificate of Correction to the Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.	8-K	3.2	03/26/2021

31.1	Certification by the Principal Executive Officer of the Registrant pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X

32.1	Certification by the Principal Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X

101.INS **	Inline XBRL INSTANCE DOCUMENT

101.SCH **	Inline XBRL TAXONOMY EXTENSION SCHEMA

101.CAL **	Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

101.DEF **	Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

101.LAB **	Inline XBRL TAXONOMY EXTENSION LABEL LINKBASE

101.PRE **	Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Management contract or compensatory plan or arrangement required to be identified pursuant to Item 15(a)(3) of this report.

Table of Contents

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q for the period ended September 30, 2025, to be signed on its behalf by the undersigned, thereunto duly authorized.

	MITESCO, INC.

Dated: November 13, 2025	By:	/s/ Mack Leath
		Mack Leath
		Chief Executive Officer, Chief Financial Officer and Principal Financial Officer

P2Y5M 0000802257 false Q3 --12-31 0000802257 2025-01-01 2025-09-30 0000802257 2025-11-13 0000802257 2025-09-30 0000802257 2024-12-31 0000802257 us-gaap:NonrelatedPartyMember 2025-09-30 0000802257 us-gaap:NonrelatedPartyMember 2024-12-31 0000802257 us-gaap:RelatedPartyMember 2025-09-30 0000802257 us-gaap:RelatedPartyMember 2024-12-31 0000802257 us-gaap:SeriesDPreferredStockMember 2025-09-30 0000802257 us-gaap:SeriesDPreferredStockMember 2024-12-31 0000802257 us-gaap:SeriesFPreferredStockMember 2025-09-30 0000802257 us-gaap:SeriesFPreferredStockMember 2024-12-31 0000802257 miti:SeriesXPreferredStockMember 2025-09-30 0000802257 miti:SeriesXPreferredStockMember 2024-12-31 0000802257 2025-07-01 2025-09-30 0000802257 2024-07-01 2024-09-30 0000802257 2024-01-01 2024-09-30 0000802257 us-gaap:NonrelatedPartyMember 2025-07-01 2025-09-30 0000802257 us-gaap:NonrelatedPartyMember 2024-07-01 2024-09-30 0000802257 us-gaap:NonrelatedPartyMember 2025-01-01 2025-09-30 0000802257 us-gaap:NonrelatedPartyMember 2024-01-01 2024-09-30 0000802257 us-gaap:RelatedPartyMember 2025-07-01 2025-09-30 0000802257 us-gaap:RelatedPartyMember 2024-07-01 2024-09-30 0000802257 us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0000802257 us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0000802257 us-gaap:CommonStockMember 2024-12-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000802257 us-gaap:RetainedEarningsMember 2024-12-31 0000802257 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000802257 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000802257 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2025-01-01 2025-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000802257 2025-01-01 2025-03-31 0000802257 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0000802257 us-gaap:CommonStockMember 2025-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000802257 us-gaap:RetainedEarningsMember 2025-03-31 0000802257 2025-03-31 0000802257 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000802257 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000802257 us-gaap:SeriesAPreferredStockMember 2025-04-01 2025-06-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000802257 miti:SeriesXPreferredStockMember 2025-04-01 2025-06-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000802257 us-gaap:SeriesDPreferredStockMember 2025-04-01 2025-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000802257 2025-04-01 2025-06-30 0000802257 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0000802257 us-gaap:CommonStockMember 2025-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000802257 us-gaap:RetainedEarningsMember 2025-06-30 0000802257 2025-06-30 0000802257 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000802257 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000802257 us-gaap:SeriesAPreferredStockMember 2025-07-01 2025-09-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000802257 miti:SeriesXPreferredStockMember 2025-07-01 2025-09-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0000802257 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000802257 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0000802257 us-gaap:CommonStockMember 2025-09-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000802257 us-gaap:RetainedEarningsMember 2025-09-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000802257 us-gaap:CommonStockMember 2023-12-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000802257 us-gaap:RetainedEarningsMember 2023-12-31 0000802257 2023-12-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2024-01-01 2024-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000802257 2024-01-01 2024-03-31 0000802257 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000802257 us-gaap:CommonStockMember 2024-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000802257 us-gaap:RetainedEarningsMember 2024-03-31 0000802257 2024-03-31 0000802257 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000802257 2024-04-01 2024-06-30 0000802257 miti:SeriesXCompensationMember miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000802257 miti:SeriesXCompensationMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000802257 miti:SeriesXCompensationMember 2024-04-01 2024-06-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2024-04-01 2024-06-30 0000802257 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000802257 us-gaap:CommonStockMember 2024-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000802257 us-gaap:RetainedEarningsMember 2024-06-30 0000802257 2024-06-30 0000802257 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000802257 us-gaap:NonrelatedPartyMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:NonrelatedPartyMember us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000802257 us-gaap:RelatedPartyMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:RelatedPartyMember us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000802257 us-gaap:SeriesFPreferredStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000802257 us-gaap:SeriesDPreferredStockMember 2024-07-01 2024-09-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0000802257 us-gaap:CommonStockMember 2024-09-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000802257 us-gaap:RetainedEarningsMember 2024-09-30 0000802257 2024-09-30 0000802257 us-gaap:AccountsPayableMember 2025-01-01 2025-09-30 0000802257 us-gaap:AccountsPayableMember 2024-01-01 2024-09-30 0000802257 us-gaap:ConvertibleNotesPayableMember us-gaap:NonrelatedPartyMember 2025-01-01 2025-09-30 0000802257 us-gaap:ConvertibleNotesPayableMember us-gaap:NonrelatedPartyMember 2024-01-01 2024-09-30 0000802257 us-gaap:ConvertibleNotesPayableMember us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0000802257 us-gaap:ConvertibleNotesPayableMember us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000802257 us-gaap:SeriesEPreferredStockMember 2025-01-01 2025-09-30 0000802257 us-gaap:SeriesEPreferredStockMember 2024-01-01 2024-09-30 0000802257 us-gaap:SeriesDPreferredStockMember 2025-01-01 2025-09-30 0000802257 us-gaap:SeriesDPreferredStockMember 2024-01-01 2024-09-30 0000802257 miti:SeriesXPreferredStockMember 2025-01-01 2025-09-30 0000802257 miti:SeriesXPreferredStockMember 2024-01-01 2024-09-30 0000802257 srt:MinimumMember 2025-01-01 2025-09-30 0000802257 srt:MaximumMember 2025-01-01 2025-09-30 0000802257 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-09-30 0000802257 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0000802257 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000802257 us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0000802257 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0000802257 us-gaap:ConvertibleDebtMember 2025-07-01 2025-09-30 0000802257 us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0000802257 us-gaap:ConvertibleDebtMember 2025-01-01 2025-09-30 0000802257 miti:CommonStockWarrantsMember 2025-07-01 2025-09-30 0000802257 miti:CommonStockWarrantsMember 2024-07-01 2024-09-30 0000802257 miti:CommonStockWarrantsMember 2025-01-01 2025-09-30 0000802257 miti:CommonStockWarrantsMember 2024-01-01 2024-09-30 0000802257 miti:AgingTopicLLCMember 2024-12-01 2024-12-06 0000802257 2024-12-06 2024-12-06 0000802257 miti:WebsiteDomainsMember 2025-09-30 0000802257 miti:WebsiteDomainsMember 2024-12-31 0000802257 miti:AccumulatedAmortizationWebsiteDomainsMember 2025-09-30 0000802257 miti:AccumulatedAmortizationWebsiteDomainsMember 2024-12-31 0000802257 miti:PPPLoanMember 2020-04-25 0000802257 2023-07-12 0000802257 2023-07-12 2023-07-12 0000802257 miti:PPPLoanMember 2023-01-01 2023-12-31 0000802257 miti:PPPLoanMember 2023-12-31 0000802257 miti:PPPLoanMember 2025-01-01 2025-09-30 0000802257 miti:KishonNoteMember 2022-05-10 2022-05-10 0000802257 miti:KishonNoteMember 2022-05-10 0000802257 miti:KishonNoteMember miti:OriginalIssueDiscountMember 2022-05-10 0000802257 srt:MinimumMember miti:KishonNoteMember 2022-05-10 0000802257 miti:KishonNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-05-10 0000802257 miti:KishonNoteMember miti:DefaultPenaltyMember 2023-12-31 0000802257 miti:KishonNoteMember 2023-12-31 0000802257 miti:KishonNoteMember 2025-09-30 0000802257 miti:KishonNoteMember 2024-12-31 0000802257 miti:FinneganNote1Member 2022-05-23 0000802257 miti:FinneganNote1Member 2022-05-23 2022-05-23 0000802257 miti:FinneganNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-23 0000802257 miti:WarrantsAt2500Member miti:FinneganNote1Member 2022-05-23 2022-05-23 0000802257 miti:WarrantsAt2500Member miti:FinneganNote1Member 2022-05-23 0000802257 miti:FinneganNote2Member 2022-05-26 0000802257 miti:FinneganNote2Member 2022-05-26 2022-05-26 0000802257 miti:FinneganNote2Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:FinneganNote2Member 2022-05-26 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:FinneganNote2Member 2022-05-26 0000802257 miti:FinneganNote3Member 2022-08-04 0000802257 miti:FinneganNote3Member 2022-08-04 2022-08-04 0000802257 miti:DragonNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-08-04 0000802257 miti:WarrantsAt2500Member miti:FinneganNote3Member 2022-08-04 2022-08-04 0000802257 miti:WarrantsAt2500Member miti:FinneganNote3Member 2022-08-04 0000802257 miti:ObligationExchangeAgreementMember miti:FinneganNote3Member 2025-04-24 2025-04-24 0000802257 miti:SchrierNoteMember 2024-12-31 0000802257 2025-05-06 2025-05-06 0000802257 2025-05-06 0000802257 2025-05-19 2025-05-19 0000802257 miti:FinneganNote3Member 2025-05-19 2025-05-19 0000802257 2025-05-19 0000802257 2025-07-21 2025-07-21 0000802257 miti:FinneganNote3Member 2025-07-21 2025-07-21 0000802257 2025-07-21 0000802257 miti:FinneganNote3Member us-gaap:RelatedPartyMember 2025-07-01 2025-09-30 0000802257 miti:FinneganNote3Member us-gaap:RelatedPartyMember 2024-07-01 2024-09-30 0000802257 miti:FinneganNote3Member us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0000802257 miti:FinneganNote3Member us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000802257 miti:FinneganNote3Member us-gaap:RelatedPartyMember 2025-09-30 0000802257 miti:FinneganNote3Member us-gaap:RelatedPartyMember 2024-12-31 0000802257 miti:FinneganNote1Member 2025-09-30 0000802257 miti:FinneganNote1Member 2024-12-31 0000802257 miti:FinneganNote2Member 2025-09-30 0000802257 miti:FinneganNote2Member 2024-12-31 0000802257 miti:FinneganNote3Member 2025-09-30 0000802257 miti:FinneganNote3Member 2024-12-31 0000802257 miti:BridgeNotesMember 2025-09-30 0000802257 miti:BridgeNotesMember 2024-12-31 0000802257 miti:LindstromNote1Member 2022-05-26 0000802257 miti:LindstromNote1Member 2022-05-26 2022-05-26 0000802257 miti:LindstromNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:LindstromNote1Member 2022-05-26 0000802257 miti:LindstromNote2Member 2022-11-29 0000802257 srt:MaximumMember miti:LindstromNote2Member 2022-11-29 0000802257 miti:LindstromNoteMember 2021-12-30 2021-12-30 0000802257 miti:ObligationExchangeAgreementMember miti:LindstromNote2Member 2025-04-24 2025-04-24 0000802257 miti:LindstromNoteMember 2024-12-31 0000802257 us-gaap:RelatedPartyMember 2025-04-01 2025-06-30 0000802257 us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0000802257 us-gaap:RelatedPartyMember 2025-01-01 2025-06-30 0000802257 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0000802257 us-gaap:RelatedPartyMember 2025-06-30 0000802257 miti:LindstromNoteMember us-gaap:RelatedPartyMember 2025-09-30 0000802257 miti:LindstromNoteMember us-gaap:RelatedPartyMember 2024-12-31 0000802257 miti:LindstromNote2Member us-gaap:RelatedPartyMember 2025-09-30 0000802257 miti:LindstromNote2Member us-gaap:RelatedPartyMember 2024-12-31 0000802257 us-gaap:SeriesAPreferredStockMember 2024-10-28 0000802257 us-gaap:SeriesAPreferredStockMember 2024-10-01 2024-10-28 0000802257 miti:ExchangeForSettlementMember us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-09-30 0000802257 miti:ExchangeForSettlementMember us-gaap:CommonStockMember 2025-01-01 2025-09-30 0000802257 miti:ExchangeForSettlementMember 2025-01-01 2025-09-30 0000802257 us-gaap:SeriesAPreferredStockMember 2025-09-30 0000802257 miti:ObligationExchangeAgreementMember 2025-01-01 2025-09-30 0000802257 us-gaap:SeriesEPreferredStockMember 2025-09-30 0000802257 us-gaap:SeriesDPreferredStockMember 2024-01-01 2024-12-31 0000802257 us-gaap:SeriesFPreferredStockMember 2025-01-01 2025-09-30 0000802257 srt:DirectorMember miti:SeriesXPreferredStockMember 2025-01-01 2025-09-30 0000802257 miti:InstitutionalInvestorAndConsultantMember miti:SeriesXPreferredStockMember 2025-01-01 2025-09-30 0000802257 miti:SeriesXPreferredStockMember 2024-01-01 2024-12-31 0000802257 miti:RangeOfExercisePrice2500Member 2025-09-30 0000802257 miti:RangeOfExercisePrice2500Member 2025-01-01 2025-09-30 0000802257 miti:RangeOfExercisePrice3750Member 2025-09-30 0000802257 miti:RangeOfExercisePrice3750Member 2025-01-01 2025-09-30 0000802257 us-gaap:FairValueInputsLevel1Member 2025-09-30 0000802257 us-gaap:FairValueInputsLevel2Member 2025-09-30 0000802257 us-gaap:FairValueInputsLevel3Member 2025-09-30 0000802257 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000802257 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000802257 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000802257 2020-11-01 0000802257 2021-10-14 0000802257 us-gaap:JudicialRulingMember 2023-12-04 2023-12-04 0000802257 2021-08-31 0000802257 us-gaap:JudicialRulingMember 2021-08-31 2021-08-31 0000802257 2021-05-24 0000802257 us-gaap:JudicialRulingMember 2024-04-02 2024-04-02 0000802257 2021-06-08 0000802257 2021-10-08 0000802257 us-gaap:JudicialRulingMember 2022-10-22 2022-10-22 0000802257 2021-09-21 0000802257 us-gaap:SettledLitigationMember 2024-04-10 2024-04-10 0000802257 2021-09-28 0000802257 us-gaap:JudicialRulingMember 2023-11-14 2023-11-14 0000802257 2021-09-28 2021-09-28 0000802257 2021-08-08 0000802257 2021-06-24 0000802257 miti:WayzettaMNMember 2025-09-30 0000802257 us-gaap:SettledLitigationMember miti:WayzettaMNMember 2025-09-30 0000802257 miti:EaganMNMember 2025-09-30 0000802257 us-gaap:SettledLitigationMember miti:EaganMNMember 2025-09-30 0000802257 miti:StLouisParkMNMember 2025-09-30 0000802257 us-gaap:SettledLitigationMember miti:StLouisParkMNMember 2025-09-30 0000802257 miti:StPaulMNMember 2025-09-30 0000802257 us-gaap:SettledLitigationMember miti:StPaulMNMember 2025-09-30 0000802257 miti:newMapleGroveMNMember 2025-09-30 0000802257 us-gaap:SettledLitigationMember miti:newMapleGroveMNMember 2025-09-30 0000802257 miti:DENVERCOMember 2025-09-30 0000802257 us-gaap:SettledLitigationMember miti:DENVERCOMember 2025-09-30 0000802257 miti:DenverCOQuincyMember 2025-09-30 0000802257 us-gaap:SettledLitigationMember miti:DenverCOQuincyMember 2025-09-30 0000802257 us-gaap:SettledLitigationMember 2025-09-30 0000802257 miti:TwoThousandTwentyFiveBridgeNotesMember us-gaap:SubsequentEventMember 2025-10-31 0000802257 miti:TwoThousandTwentyFiveBridgeNotesMember us-gaap:SubsequentEventMember 2025-10-31 2025-10-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares miti:Sqft xbrli:pure miti:creditor

Mitesco, Inc. 10-Q